Quarterly ResultAug 6, 2026, 04:23 PM
Cytokinetics Q2 Net Product Revenue $25.3M; Net Loss $(198.8)M
AI Summary
Cytokinetics reported its second quarter 2026 financial results, with MYQORZO net product revenue reaching $25.3 million. The company posted a net loss of $(198.8) million, or $(1.50) per share, on total revenues of $28.6 million. Cytokinetics ended the quarter with approximately $1.7 billion in cash, cash equivalents, and investments, bolstered by $760.1 million from a recent public offering. The company also announced positive topline results from the ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM) and plans to submit a Supplemental NDA in Q4 2026, while updating its full-year 2026 expense guidance.
Key Highlights
- MYQORZO net product revenue reached $25.3 million in Q2 2026.
- Total revenues for Q2 2026 were $28.6 million, down from $66.8 million in Q2 2025.
- Net loss for Q2 2026 was $(198.8) million, or $(1.50) per share.
- Cash, cash equivalents, and investments totaled ~$1.7 billion as of June 30, 2026.
- Net proceeds from a recent public offering were approximately $760.1 million.
- R&D expenses were $97.8 million and SG&A expenses were $104.4 million in Q2 2026.
- Updated 2026 GAAP combined R&D and SG&A expense guidance to $860 million to $890 million.
- ACACIA-HCM Phase 3 trial for aficamten in nHCM met both dual primary endpoints.
Price Impact
More from CYTK